Stock Watch: A Biotech Holiday Horror Story
Unlike In Christmas Movies, Companies Can Have Unhappy Endings
Cyclacel’s long demise as a therapeutic oncology biotech company followed a parade of red flags over nearly 25 years. Only one should have been needed to dissuade investors.
